(Q39904370)

15 September 2017

Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG. (English)

1 reference

15 September 2017

Lamont J Barlow

1

1 reference

15 September 2017

Catherine M Seager

series ordinal

2

1 reference

15 September 2017

Mitchell C Benson

series ordinal

3

1 reference

15 September 2017

James M McKiernan

series ordinal

4

1 reference

15 September 2017

1 January 2010

1 reference

15 September 2017

1 reference

15 September 2017

28

1 reference

15 September 2017

1

1 reference

15 September 2017

108-111

1 reference

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

15 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.029

A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.029

Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.029

Defining bacillus Calmette-Guerin refractory superficial bladder tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.029

The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.029

Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.029

Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.029

New drugs and new approaches for the treatment of metastatic urothelial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.029

Bladder tissue pharmacokinetics of intravesical taxol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.029

Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.029

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.029

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.029

Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.029

Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.029

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.029

Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.029

Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.029

Molecular analysis of PTEN and MXI1 in primary bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.029

Molecular pathogenesis and diagnostics of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.029

Inactivation of p53 and Pten promotes invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.029

10.1016/J.UROLONC.2009.03.029

7 January 2021

Identifiers

DOI

1 reference

15 September 2017

1 reference